UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interpreting plasma estrogen levels in breast cancer: caution needed

Journal of clinical oncology, 2014-05, Vol.32 (14), p.1396-1400

2014

Volltextzugriff (PDF)

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Journal of clinical oncology, 2012-03, Vol.30 (7), p.709-717

2012

Volltextzugriff (PDF)

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1580-1583

2016

Volltextzugriff (PDF)

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2444-2447

2006

Volltextzugriff (PDF)

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5126-5137

2005

Volltextzugriff (PDF)

Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4859-4861

Lønning, Per E

2008

Volltextzugriff (PDF)

Endocrine effects of aromatase inhibitors

Journal of clinical oncology, 2010-02, Vol.28 (6), p.e101-e102

2010

Volltextzugriff (PDF)

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Clinical cancer research, 2022-11, Vol.28 (21), p.4714-4723

2022

Volltextzugriff (PDF)

Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

Clinical cancer research, 2008-10, Vol.14 (19), p.6330-6335

2008

Volltextzugriff (PDF)

Intratumoral Estrogen Disposition in Breast Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1790-1801

2010

Volltextzugriff (PDF)

Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation

Clinical cancer research, 2011-08, Vol.17 (15), p.4948-4958

2011

Volltextzugriff (PDF)

Long-Term Follow-Up of the Intergroup Exemestane Study

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2507-2514

2017

Volltextzugriff (PDF)

The multitude of molecular analyses in cancer: the opening of Pandora’s box

Genome Biology, 2014-09, Vol.15 (9), p.447-447, Article 447

2014

Volltextzugriff (PDF)

Aromatase inhibitors and inactivators for breast cancer therapy

Drugs & aging, 2002, Vol.19 (4), p.277-298

LØNNING, Per E

2002

Volltextzugriff (PDF)

The Potential for Aromatase Inhibition in Breast Cancer Prevention

Clinical cancer research, 2001-12, Vol.7 (12), p.4423s

2001

Volltextzugriff (PDF)

Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement

Clinical cancer research, 2005-01, Vol.11 (2 Pt 2), p.861s-864s

2005

Volltextzugriff (PDF)

Influence of Aromatase Inhibitors on Plasma Total Homocysteine in Postmenopausal Breast Cancer Patients

Clinical chemistry (Baltimore, Md.), 1999-02, Vol.45 (2), p.252-256

1999

Volltextzugriff (PDF)

Gene Expression Profiling of Breast Cancer in Relation to Estrogen Receptor Status and Estrogen-Metabolizing Enzymes: Clinical Implications

Clinical cancer research, 2005-01, Vol.11 (2), p.878s-883s

2005

Volltextzugriff (PDF)

Genome sequencing for personalized cancer treatment

Tidsskrift for den Norske Lægeforening, 2012-11, Vol.132 (21), p.2406-2408

2012

Volltextzugriff (PDF)

Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact

Journal of clinical oncology, 2002-07, Vol.20 (13), p.3039-3040

2002

Volltextzugriff (PDF)

Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients

Clinical cancer research, 1996-09, Vol.2 (9), p.1515-1521

1996

Volltextzugriff (PDF)

Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients

Clinical cancer research, 1998-09, Vol.4 (9), p.2125-2128

1998

Volltextzugriff (PDF)

Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma

Cancer, 1999-02, Vol.85 (4), p.891-898

1999

Volltextzugriff (PDF)

Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer

Clinical pharmacology and therapeutics, 1984-12, Vol.36 (6), p.796-802

1984

Volltextzugriff (PDF)

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

Journal of clinical oncology, 2002-02, Vol.20 (3), p.751-757

2002

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

ThemaBreast Cancer

KollektionPublisher or Other Site

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(43)

Sprache

Englisch
(42)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Interpreting plasma estrogen levels in breast cancer: caution needed

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?

Endocrine effects of aromatase inhibitors

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

Intratumoral Estrogen Disposition in Breast Cancer

Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation

Long-Term Follow-Up of the Intergroup Exemestane Study

The multitude of molecular analyses in cancer: the opening of Pandora’s box

Aromatase inhibitors and inactivators for breast cancer therapy

The Potential for Aromatase Inhibition in Breast Cancer Prevention

Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement

Influence of Aromatase Inhibitors on Plasma Total Homocysteine in Postmenopausal Breast Cancer Patients

Gene Expression Profiling of Breast Cancer in Relation to Estrogen Receptor Status and Estrogen-Metabolizing Enzymes: Clinical Implications

Genome sequencing for personalized cancer treatment

Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact

Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients

Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients

Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma

Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

Aktive Filter

Suchergebnisse filtern